The U.S. government pledged $2.1 billion to pharmaceutical companies GlaxoSmithKline and Sanofi Pasteur for the production of up to 100 million doses of COVID-19 vaccines as well as tests and treatments.

“The global need for a vaccine to help prevent COVID-19 is massive, and no single vaccine or company will be able to meet the global demand alone,” said Thomas Triomphe, the executive vice president of Sanofi Pasteur. “With our partner GSK, we expect our Phase 1/2 study for the recombinant adjuvanted approach to start in September.”